Research reveals that a FGFR3 decoy receptor can reduce the transition of lung fibroblasts to myofibroblasts, potentially offering a new therapeutic approach for pulmonary fibrosis. This study highlights the role of FGFR3 in the disease's pathology.
fgfr3 decoy receptor attenuates lung fibroblast to myofibroblast transition and pulmonary fibrosis
Original title: “A FGFR3 decoy receptor attenuates lung fibroblast-to-myofibroblast transition and pulmonary fibrosis.”